CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

CytoSorbents today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), has awarded the Company a three-year contract valued at up to $4,421,487 as part of a Peer-Reviewed Medical Research Program Technology/Therapeutic Development Award to complete preclinical development of the HemoDefend™-BGA plasma and whole blood adsorber.

The HemoDefend-BGA filter is designed to enable “universal plasma”, or plasma that can be administered to anyone regardless of blood type, and to improve the safety of whole blood transfusions, by the rapid and efficient removal of anti-A and anti-B antibodies from these two blood products.

This award augments the previously awarded Defense Health Agency Small Business Technology Transfer (STTR) Phase 3 contract of $2,897,172. Funds provided by the CDMRP award will be allocated to complete preclinical development (e.g. final device design, device verification and validation testing, biocompatibility, and sterilization validation testing), the establishment of quality documentation in conformity with CytoSorbents’ certificated, full quality management and quality assurance system, and building clinical inventory.  The goal of the program is to obtain an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to move forward with clinical studies.

Dr. Maryann Gruda, Ph.D., Principal Investigator and Director of Biology of CytoSorbents stated, “We are grateful for the U.S. Army’s strong support and funding of our HemoDefend-BGA technology, which will help us advance it more rapidly to commercialization.  We believe the BGA adsorber will have a momentous impact on the availability of universal plasma and low titer O whole blood (LTOWB) to prevent unnecessary loss of warfighter and civilian life.”

Dr. Phillip Chan, MD, Ph.D., Chief Executive Officer of CytoSorbents, “Hemorrhage from battlefield injuries and civilian trauma is a leading cause of preventable death.  The broader availability of safe blood products that can help resuscitate patients is a key to survival.  Our goal is to leverage this new award to rapidly bring the HemoDefend-BGA anti-A and anti-B adsorber to the markets globally to help save lives.”

The HemoDefend-BGA Adsorber is not yet approved in the U.S. or elsewhere. The U.S. Army Medical Research Acquisition Activity (USMRAA), 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office for this Award (No. W81XWH2010712). This follows the successful completion of Phase I and II STTR contracts of approximately $1.15 million with researchers at Penn State University, previously funded by the U.S. Army Medical Research Acquisition Activity (USAMRAA) and the U.S. Army Medical Research and Material Command (USAMRMC).

The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Army and the Department of Defense.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.